ESMO 2024 – Astellas defends its degrader
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.
What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.
If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.
Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?
Early data on Rybrevant plus chemo have spurred a quick leap into pivotal trials.
Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.
Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.
The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.